Know What's Happening in Industry

Vaccine Protects Against Multiple Respiratory Viruses, Bacteria, and Allergens in Mice

Stanford researchers have created an intranasal vaccine that elicits a combined innate‑adaptive response, providing broad lung protection in mice. The formulation, containing TLR agonists and a harmless antigen, shielded animals for at least three months against SARS‑CoV‑2, other coronaviruses, two major bacterial pathogens, and even dust‑mite‑induced allergic asthma. By mimicking immune communication signals rather than specific antigens, the approach aims to generate durable, tissue‑localized immunity. The team plans pre‑clinical optimization and IND‑enabling studies, targeting human trials within the next few years.